Hemophilia A Clinical Trials

16 studies are recruiting for hemophilia a in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Iowa City, Iowa 4 Seattle, Washington 4 Indianapolis, Indiana 3 Philadelphia, Pennsylvania 3

Studies now recruiting

  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

    WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a mult…

    Stage
    Phase 1
    Ages
    2 to 59
    Site
    UC Davis Cancer Center, Sacramento, California
    Locations
    14 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT05987449 on ClinicalTrials.gov

  2. A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

    This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Center for Inherited Blood Disorders, Orange, California
    Locations
    3 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07226206 on ClinicalTrials.gov

  3. A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

    The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without FVIII inhibitors. The study will include people aged ≥12 y…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado
    Locations
    27 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07416526 on ClinicalTrials.gov

  4. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

    The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    Center for Inherited Blood Disorders, Orange, California
    Locations
    42 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07416604 on ClinicalTrials.gov

  5. SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

    The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.

    Stage
    Phase 3
    Ages
    6 and older
    Site
    Children's Healthcare of Atlanta, Atlanta, Georgia
    Locations
    2 in total
    Run by
    Emory University

    See if you can join NCT04563520 on ClinicalTrials.gov

  6. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

    The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study will open e…

    Stage
    Phase 3
    Ages
    1 to 17
    Site
    Intermountain - Primary Children's Hospital, Salt Lake City, Utah
    Locations
    64 in total
    Run by
    Pfizer

    See if you can join NCT05611801 on ClinicalTrials.gov

  7. Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

    Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive …

    Stage
    Not phased
    Ages
    6 to 19
    Site
    Arkansas Children's Hospital, Little Rock, Arkansas
    Locations
    10 in total
    Run by
    Wayne State University

    See if you can join NCT05022459 on ClinicalTrials.gov

  8. A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII…

    Stage
    Phase 1
    Ages
    18 to 60
    Site
    Children's Hospital Los Angeles, Los Angeles, California
    Locations
    10 in total
    Run by
    Equilibra Bioscience LLC

    See if you can join NCT06349473 on ClinicalTrials.gov

  9. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

    Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approxima…

    Stage
    Phase 3
    Ages
    1 to 74
    Site
    Northwell Health HTC, New Hyde Park, New York
    Locations
    75 in total
    Run by
    Pfizer

    See if you can join NCT05145127 on ClinicalTrials.gov

  10. A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

    This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study wi…

    Stage
    Phase 4
    Ages
    12 and older
    Site
    Children's Hospital Los Angeles- Site Number : 8400005, Los Angeles, California
    Locations
    2 in total
    Run by
    Sanofi

    See if you can join NCT06145373 on ClinicalTrials.gov

  11. Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

    A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Regents of the University of California||UC Davis Health, Rancho Cordova, California
    Locations
    23 in total
    Run by
    Pfizer

    See if you can join NCT05568719 on ClinicalTrials.gov

  12. Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

    Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery

    Stage
    Phase 4
    Ages
    12 and older
    Site
    UT Health San Antonio, San Antonio, Texas
    Locations
    16 in total
    Run by
    Octapharma

    See if you can join NCT05936580 on ClinicalTrials.gov

  13. ATHNdataset Registry

    The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of in…

    Stage
    Not phased
    Ages
    Any age
    Site
    American Thrombosis and Hemostasis Network, Hickory, North Carolina
    Run by
    American Thrombosis and Hemostasis Network

    See if you can join NCT06820515 on ClinicalTrials.gov

  14. Hemophilia A Research Program

    This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study follows mother-child pairs, the study includes both a maternal cohort and a pediatric cohort. Each cohort has a primary goal: for the mother wi…

    Stage
    Not phased
    Ages
    Any age
    Site
    University of Washington, Seattle, Washington
    Run by
    University of Washington

    See if you can join NCT07414511 on ClinicalTrials.gov

  15. Treatment of Hemophilia A Patients With FVIII Inhibitors

    This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with ha…

    Stage
    Not phased
    Ages
    Any age
    Site
    Arthur M. Blank Hospital, Atlanta, Georgia
    Locations
    2 in total
    Run by
    Emory University

    See if you can join NCT04023019 on ClinicalTrials.gov

  16. ASC618 Gene Therapy in Hemophilia A Patients

    Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, en…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Arkansas Children's Hospital, Little Rock, Arkansas
    Run by
    ASC Therapeutics

    See if you can join NCT04676048 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.